Eli Lilly's (LLY) Oral GLP-1, Orforglipron, delivered superior blood sugar control and weight loss compared to oral Semaglutide in head-to-head Type 2 Diabetes trial, published in the Lancet
Context
Eli Lilly's new oral GLP-1 drug, Orforglipron, has shown superior results in blood sugar control and weight loss compared to Semaglutide in a recent Type 2 Diabetes trial. This could position Eli Lilly favorably in the competitive diabetes treatment market, potentially enhancing their revenue outlook and impacting peer companies in the pharmaceuticals sector.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#ELI LILLY & CO#LLY.US#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#US EQUITIES